Navigation Links
Boehringer Ingelheim Presents Progression-Free Survival Data for Investigational Afatinib and Nintedanib in Advanced NSCLC
Date:5/15/2013

(GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.  Poster discusison (Abstract #8016) at American Society of Clinical Oncology, Chicago, June 2, 2013.

[2]  Hanna, N., MD. LUME-Lung 2: A multicenter, randomized, double-blind, phase 3 study of nintedanib plus pemetrexed vs placebo plus pemetrexed in patients with advanced non-squamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. Poster discussion (Abstract #8034) at American Society of Clinical Oncology, Chicago, June 2, 2013.

[3] Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer  Drugs and Biologics. May 2007. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071590.pdf

[4]   National Center for Biotechnology Information (NCBI). Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? December 2010. Available at: http://www.ncbi.nlm.nih.gov/pubmed/21268434

[5] Geater, S.L., MD.  LUX-Lung 6: Patient reported outcomes (PROs) from a randomized open-label, Phase III study in 1st-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations. Poster (Abstract #8061) at American Society of Clinical Oncology, Chicago, June 1, 2013.

[6]   European Organisation for Research and Treatment of Cancer (EORTC). Glossary. Available at: http://groups.eortc.be/qol/glossary. Last accessed May 9, 2013.

[7]  Mayo Clinic. Elevated Liver Enzymes
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2014)... 12, 2014 Sepsis is a life ... worldwide.  Education and awareness are fundamental to improving ... marks Sepsis Awareness Month and September 13 th ... Sepsis Alliance, "Sepsis, the body,s toxic reaction to ... every year, and thousands more are left with ...
(Date:9/11/2014)... , September 11, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/lqkmlx/radio_frequency ) has announced the ... Identification (RFID) Market in Healthcare (Tags, ... Industry Analysis, Size, Share, Growth, Trends ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:9/11/2014)... , Sept. 11, 2014 Array BioPharma Inc. ... focused on the discovery, development and commercialization of ... cancer, today announced the appointment of Victor ... Sandor will be responsible for leading clinical, medical ... portfolio, including binimetinib, a MEK inhibitor in Phase ...
Breaking Medicine Technology:Nanomix Supports Sepsis Awareness 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 2Global Radio Frequency Identification (RFID) Market in Healthcare (Tags, Readers, Middleware, Printers and Cabinets) - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2020 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 2Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 3Array BioPharma Appoints Victor Sandor, M.D., As Chief Medical Officer 4
(Date:9/14/2014)... Aliso Viejo, California (PRWEB) September 14, 2014 ... Pixel Film Studios, announces the production of the Flip ... X . , "Flip Flop is a simple-to-use and ... professional themed video with ease in Final Cut Pro ... "With 48 camera options and On-Screen controls, the user ...
(Date:9/14/2014)... is an internationally well-known designer and leader in the ... of cocktail dresses under $100 . To attract ... the company is also providing big savings for its ... black formal gowns and so on. The current discount ... company’s senior spokesman says, “We are pleased to announce ...
(Date:9/13/2014)... 2014 Over the past five ... in Australia have shown signs of struggle. ... confectionery goods has caused Australian consumers to turn ... to IBISWorld industry analyst Ryan Lin. This trend ... of health consciousness, which has alerted the Australian ...
(Date:9/13/2014)... Ticket Down is a dependable source for ... group that originally formed in 1994 in Los Angeles, California, ... group had been anticipating a new album since 2012 when ... about the release of their new album, they will be ... worldwide tour beginning in the United States in February. The ...
(Date:9/13/2014)... September 13, 2014 Healthcare employers, ... manufacturers turn to operators in the Healthcare ... manage risk. “Over the past five years, demand ... advances in the healthcare sector and the changing ... Phillips. Moreover, the 2010 Patient Protection and Affordable ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios Releases Flip Flop Theme for Final Cut Pro X Users 2Health News:UWDress.com: Elegant Cocktail Dresses Under $100 Now Offered 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 2Health News:Confectionery Manufacturing in Australia Industry Market Research Report Now Available from IBISWorld 3Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 2Health News:Maroon 5 Tickets Now on Sale in Philadelphia, Washington DC, Nashville, San Jose, Chicago, Dallas, Los Angeles, Tacoma, Saint Paul, Vancouver, San Diego & New York 3Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Healthcare Consultants in the US Industry Market Research Report from IBISWorld Has Been Updated 3
... variant ups violence inclination, study finds , WEDNESDAY, June 17 (HealthDay ... for boys joining violent street gangs. But a new study finds ... part, in their genes. , Boys who have a variant of ... "warrior gene" -- are not only more likely to be in ...
... effective after heart attack and stroke , WEDNESDAY, June 17 ... the risk of stroke, heart attack and death in patients ... angina, a new trial shows. , Rivaroxaban is a pill ... In earlier studies, the drug was effective in preventing venous ...
... N.J., June 17 Nuvilex, Inc. (OTC Bulletin Board: ... that it has renewed its Master Distribution Agreement with ... and aesthetic solutions, for the distribution and sale of ... , The renewal is for one year and ...
... Sciences Category , , SUNNYVALE, Calif., June 17 ... ARAY ), a global leader in the field of radiosurgery, ... CEO, received the Ernst & Young Entrepreneur Of The Year(R) ... Northern California. According to Ernst & Young LLP, the ...
... , HERLEV, Denmark, June 17 A leading Danish cancer ... installing eight advanced radiotherapy treatment machines from Varian Medical Systems ... Herlev Hospital, to the north-west of Copenhagen, delivered ... patient using a Clinac(R) iX linear accelerator. , , ...
... Therapeutics, Inc. (OTC Bulletin Board: ECTE) announced today ... Handok Pharmaceuticals Co., Ltd. ("Handok"), the largest diabetes ... Echo granted Handok rights to develop, market, sell ... painless, needle-free, transdermal, continuous glucose monitoring ("tCGM") in ...
Cached Medicine News:Health News:Boys May Feel a Genetic Pull Toward Gangs 2Health News:New Anticoagulant Pill Works Well in Trial 2Health News:New Anticoagulant Pill Works Well in Trial 3Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 2Health News:Nuvilex Renews MedX Master Distribution Agreement and Implements New Pricing for Talsyn Scar Cream 3Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 2Health News:Accuray's Euan Thomson Named Ernst & Young Entrepreneur Of The Year(R) 2009 Award Recipient in Northern California 3Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 2Health News:Prostate Cancer Patient Receives First RapidArc Radiotherapy Treatment at Major Danish Hospital 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 2Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 3Health News:Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System 4
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: